Meta-Analyses of Randomized Controlled Clinical Trials to Evaluate the Safety of Human Drugs or Biological Products
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
November 7, 2018
April 27, 2020
0ed49ff3-89c9-4436-8c06-0324d3e2aff2
Related Documents
Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products: Draft Guidance for Industry
Guidance DocumentJanuary 9, 2026Center for Drug Evaluation and Research
Integrating Randomized Controlled Trials for Drug and Biological Products Into Routine Clinical Practice: Draft Guidance for Industry
Guidance DocumentSeptember 18, 2024Center for Drug Evaluation and Research
Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products
Guidance DocumentFebruary 1, 2023Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox